Novel Device to Optimize Aerosol Drug Delivery for Pulmonary Hypertension Treatment

优化肺动脉高压治疗气雾剂药物输送的新型装置

• 批准号: 10698474
• 负责人: John E Porterfield
• 金额: $ 101.31万
• 依托单位: BRIDGESOURCE MEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10698474
• 关键词: Academic Medical Centers; Aerosols; Affect; Air Movements; Area; Arteries; Back; Blood capillaries; Breathing; Cessation of life; Clinical; Clinical Research; Consult; Custom; Deposition; Development; Device Designs; Devices; Diagnosis; Disease; Disease Management; Dose; Drug Delivery Systems; Drug Formulations; Equilibrium; Exhalation; Formulation; Goals; Heart; Heart failure; Hour; Housing; Iloprost; Inhalation; Inhalation Therapy; Interstitial Lung Diseases; Lead; Leadership; Left; Life; Life Expectancy; Lung; Lung diseases; Medial; Medical; Nebulizer; Oral; Particle Size; Pathway interactions; Patient Monitoring; Patients; Pattern; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Pharyngeal structure; Phase; Physician Executives; Population; Population Sizes; Positioning Attribute; Principal Investigator; Prognosis; Prostaglandins; Pulmonary Hypertension; Radial; Research; Respiration; Respiration Disorders; Respiratory Therapy; Small Business Innovation Research Grant; Speed; Spottings; System; Techniques; Testing; Texas; Time; United States Food and Drug Administration; Universities; aerosolized; austin; commercialization; compliance behavior; design verification; effective therapy; experience; expiration; hypertension treatment; improved; improved outcome; invention; mechanical force; medication administration; meter; miniaturize; novel; older patient; particle; pressure; pulmonary arterial hypertension; respiratory; sensor; side effect; therapeutic target; tool; wasting

Abstract Aerosol inhalation therapy is one of the cornerstones of respiratory therapy. The size of airborne particles determines their deposition pattern within the lungs and therefore, the efficacy of inhalation therapy. In this Phase 2 SBIR project, BridgeSource Medical (BSM) proposes to develop a breath-adaptive nebulizer with variable aerosol droplet sizes and actuation times. This can be used to administer precise doses of pharmaceutical drugs to the pulmonary system with much greater efficiency than currently available aerosol delivery devices like small-volume adaptive aerosol delivery (AAD) nebulizers that require strict patient breath timing, but do not vary droplet size. The nebulizer would be particularly beneficial in the administration of medications to treat elderly patients with respiratory conditions such as pulmonary hypertension, where long treatment times and strict requirements on patient breathing lead to poor compliance. The ultimate goal will be to develop a clinical tool that would be approved by the Food and Drug Administration (FDA) as an effective system to nebulize several drug formulations targeted for patients who cannot easily comply with strict breathing maneuvers, such as the those with advanced lung disease such as pulmonary hypertension.

摘要 雾化吸入治疗是呼吸治疗的基石之一。空中的大小 颗粒决定了它们在肺内的沉积模式， 吸入疗法在该第2阶段SBIR项目中，BridgeSource Medical（BSM）建议 开发具有可变气溶胶液滴尺寸和致动时间的呼吸适应性雾化器。 这可以用来管理精确剂量的药物，以肺部系统 其效率比目前可用的气溶胶输送装置 自适应气雾剂输送（AAD）雾化器，需要严格的患者呼吸定时，但不 改变液滴大小。雾化器在施用以下药物中将是特别有益的： 用于治疗患有呼吸疾病如肺动脉高压的老年患者的药物， 治疗时间长和对患者呼吸的严格要求导致不良的 合规最终目标是开发一种临床工具， 美国食品和药物管理局（FDA）作为一个有效的系统，雾化多种药物 针对不能容易地遵守严格呼吸操作的患者的制剂， 例如患有肺动脉高压等晚期肺部疾病的人。